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ABSTRACT The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies patients
with chronic obstructive pulmonary disease (COPD) into four groups (A to D).
We explored the characteristics, stability and relationship to outcomes of these groups within the
ECLIPSE study (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points)
(n52101).
Main results showed that: 1) these groups differed in several clinical, functional, imaging and biological
characteristics in addition to those used for their own definition; 2) A and D groups were relatively stable
over time, whereas groups B and C showed more temporal variability; 3) the risk of exacerbation over
3 years increased progressively from A to D, whereas that of hospitalisation and mortality were lowest in A,
highest in D and intermediate and similar in B and C, despite the former having milder airflow limitation.
The prevalence of comorbidities and persistent systemic inflammation were highest in group B.
The different longitudinal behaviour of group A versus B and C versus D (each pair with similar forced
expiratory volume in1 s (FEV1) values supports the 2011 GOLD proposal of assessing COPD patients by
more than FEV1 only. However the assumption that symptoms do not equate to risk appears to be naı¨ve, as
groups B and C carry equally poor clinical outcomes, though for different reasons.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease, and the forced expiratory
volume in the 1 s (FEV1) does not describe this complexity fully [1]. The recently released 2011 Global
Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations recognise this limitation and
propose a novel multidimensional approach to assess COPD patients, which includes the level of symptoms
(as assessed by either the modified Medical Research Council (mMRC) score or the chronic obstructive
pulmonary disease (COPD) Assessment Test (CAT), the FEV1 value (expressed as a percentage of predicted
value) and the individual history of previous exacerbations [2]. As a result, COPD patients can now be
categorised and treated according to four groups (A, B, C and D) [2].
Very recently, three studies have used existing cohorts of COPD patients to explore different aspects of this
new GOLD assessment proposal. HAN et al. [3] used the COPDGene cohort [4] to explore the influence of
the instrument used to assess the level of symptoms (mMRC versus the St. George’s Respiratory
Questionnaire (SGRQ), as a surrogate for CAT) on group assignment and risk of exacerbations during
follow-up. LANGE et al. [5] investigated the ability of the 2011 GOLD proposal to predict the clinical course
of the disease in two Danish general population cohorts combined [5]. Finally, SORIANO et al. [6]
determined the distribution and validity of the four GOLD 2011 groups as predictors of mortality in eleven
small Spanish cohorts merged for the analysis.
The ECLIPSE study(Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) is a
large, observational, longitudinal, multicentre, international study that includes a very detailed, clinical,
functional imaging, and biological characterisation of COPD patients with a 3-year follow-up[1, 7].
Therefore, it offers a unique opportunity to reproduce some of these previous analyses and to explore other
novel aspects of potential relevance. Specifically, in this study we used the ECLIPSE cohort to: 1) compare
the 2007 and 2011 GOLD recommendations, in terms of patient distribution and assessment of disease
severity; 2) characterise in detail the four 2011 GOLD groups; 3) explore their stability after a 3-year follow-
up; and 4) investigate their relationship with clinical relevant outcomes (exacerbations, hospitalisations and
mortality), and identify significant risk factors.
Methods
Study design
The design of the ECLIPSE study has been previously published [7]. In brief the ECLIPSE study is an
observational, longitudinal, controlled study that recruited patients who mostly attended the outpatient
clinics of secondary or tertiary care hospitals and, occasionally, primary care. After a baseline visit,
participants were evaluated at 3 months, 6 months and then every 6 months for 3 years. ECLIPSE complies
with the Declaration of Helsinki and Good Clinical Practice Guidelines, and has been approved by the ethics
committees of the participating centres. All participants provided written informed consent.
Population
The original ECLIPSE cohort included 2164 patients with COPD, as previously published [1]. Since the
mMRC dyspnoea score was missing in 62 patients and one patient had an unknown GOLD stage, the
present analysis includes 2101 GOLD stage I–IV patients (97% of the original ECLIPSE cohort) with full
2011GOLD data. These 2101 patients were categorised into one of four groups (A, B, C or D) according to
the 2011 GOLD recommendations [2] using the mMRC score (the CAT had not been published [8] when
the ECLIPSE study was designed [7]) and the FEV1 value, both of which were measured at recruitment, as
well as the number of exacerbations retrospectively recorded from the year before inclusion in the ECLIPSE
study.
Measurements
The methodology used in ECLIPSE has also been reported in detail elsewhere [1, 7]. We used standardised
questionnaires to record dyspnoea (mMRC), comorbidities (American Thoracic Society and Division of
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Lung Disease of the National Institute of Health questionnaire (ATS-DLD-78-adult)), health-status (St.
George’s Respiratory Questionnaire for COPD patients (SGRQ-C)) and depression (Center for
Epidemiological Studies Depression Scale (CES-D)) [1, 7]. Nutritional status was assessed by the body
mass (BMI) and fat-free mass indexes (FFMI) by bioelectrical impedance [7]. COPD exacerbations
requiring treatment with antibiotics, oral corticosteroids and/or hospitalisation in the year prior to the
study (and during follow-up) were also recorded. Spirometry and the 6-min walking distance (6MWD)
were performed according to international guidelines [9, 10]. Spirometric reference values were those of the
European Community for Coal and Steel (ECCS) [11]. The BMI, airflow obstruction, dyspnoea, exercise
capacity (BODE) index was calculated according to CELLI et al. [12]. All subjects underwent a low-dose
computed tomography (CT) scan of the chest acquired using multi-detector-row CT scanners (GE
Healthcare or Siemens Healthcare), as described elsewhere [1]. Hospitalisations and all-cause mortality were
recorded during a 3-year follow-up [13, 14]. Finally, the annual rate of FEV1 decline in each patient [15]
and the proportion of patients with persistent systemic inflammation at baseline [14] were calculated as
reported previously and included in the current analysis.
Statistical analysis
Results are shown as mean¡SD or proportion, as appropriate. Jonckheere–Terpstra tests were used to assess
differences in subject characteristics among groups with ordering of AfBfCfD [16]. Kaplan–Meier
curves were constructed to describe the occurrence of exacerbations, hospitalisations and all-cause mortality
over the study period for both the 2007 [17] and 2011 GOLD [2] classifications. Concordance probabilities
and their associated 95% confidence intervals were calculated for Cox regression models for exacerbations,
hospitalisations and all-cause mortality to evaluate the predictive accuracy of the 2007 and 2011 GOLD
classifications [18]. A Cox proportional hazards regression model was used to identify factors associated
with increased risk of mortality and hospitalisation, A p-value ,0.05 (two sided) was considered statistically
significant.
Results
Patient distribution and assessment of disease severity by the 2007 and 2011 GOLD
recommendations
Figure 1 shows the distribution of the COPD patients included in the analysis according to the 2007 (fig 1a)
and 2011 (fig 1b) GOLD recommendations. The latter resulted in a rightward shift of the distribution,
indicating that more patients were being classified in more severe groups. The mean¡SD 2007 GOLD stage
was not different between groups A (2.0¡0.0) and B (2.0¡0.1), and only slightly worse (albeit statistically
significantly p,0.001) between groups C (3.0¡0.5) and D (3.2¡0.6). Figure 1c also shows the cumulative
distribution of the four 2011 GOLD groups within each 2007 GOLD stage. GOLD stage II includes a large
proportion of group A (54%) and B (32%) patients but also some group C (7%) and D patients (8%).
Since, by definition, GOLD stage II patients must have an FEV1 o50% pred [17], these latter two groups
were classified as high risk groups (C or D) exclusively, because of their past exacerbation history (o2 per
year.). Alternatively, also by definition, GOLD stages III and IV cannot include group A or B patients, where
FEV1 must be o50% of reference [2]. There were more group D patients in GOLD stage IV than GOLD
stage III (fig. 1c). The frequency distribution of these four groups was not different in males and females
(online supplementary table 1E).
Characterisation of the 2011 GOLD groups
The application of the 2011 GOLD assessment criteria resulted in the expected differences in the mMRC
scores, FEV1 and exacerbation rates between the four groups (table 1). In addition, these four groups
differed also in many of the other characteristics studied (tables 1 and online supplementary table 2E). It is
of note that some variables were particularly abnormal in the two high symptoms groups (B and D; SGRQ-
C and CES-scores, many comorbid conditions, exercise capacity and most inflammatory biomarkers),
whereas others were mostly abnormal in the two high risk groups (C and D; amount of emphysema present
and arterial oxygenation saturation) (tables 1 and online supplementary table 2E). Finally, of note, age,
gender, cumulative smoking exposure, FEV1 reversibility and the annual rate of FEV1 decline were either
not different between groups or differences were of unlikely clinical relevance (tables 1 and online
supplementary table 2E).
As in two previous studies [4, 5], we stratified the C and D groups further according to the specific criteria
that determined the inclusion of patients in these high risk groups (FEV1,50% reference (C1 or D1),
exacerbation history o2 years. (C2 or D2) or both (C3 or D3)). An FEV1 ,50% of reference alone was the
most frequent reason to classify a patient as high risk in either the C or D groups (70% and 63% of cases,
respectively), whereas the presence of frequent exacerbations alone was responsible for a much lower
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proportion of patients (13% and 9%, respectively); the remaining patients (18% and 28%, respectively)
were classified as C or D patients because of the presence of both low FEV1 and frequent exacerbations.
Online supplementary tables 3E and 4E present the main characteristics of these three C and D subgroups.
By definition, exacerbation frequency was particularly high in C2/D2 and C3/D3.
Temporal stability of the 2011 GOLD groups during the 3-year follow-up
Figure 2 presents the distribution of the four 2011 GOLD groups both at recruitment and 3 years later.
However, it is important to note that not all patients studied at recruitment contributed data during the 3-
year follow-up, due to a variety of reasons that include death, drop-out, lost for follow-up and/or missing
data. This effect was less marked in group A, worse in group D and intermediate in groups B and C. With
this caveat in mind, it is interesting to see that the relative majority of A and D patients do remain in their
original classification, whereas B and C patients have greater temporal variability (fig. 2). B patients either
remained in the same category (B), improved (A) or deteriorated (D) in roughly similar proportions. By
contrast C patients, either remained stable (C) or deteriorated (D) and only a relatively small fraction
improved (B or A). Finally, it is of note that the proportion of patients that moved to group A from B, C or
D was lowest in D, intermediate in C and largest in B (fig. 2).
Relationship with long-term outcomes: comparison of the 2007 and 2011 GOLD recommendations
Figure 3 presents Kaplan–Meier curves that describe the occurrence of exacerbations (a, d and g),
hospitalisations (b, e and h) and all-cause mortality (c, f and i) over the study period for 2007 GOLD stages
in all patients (a–c), 2011 GOLD groups in all patients (d–f) and 2011 GOLD groups for patients with a
FEV1,50% reference (GOLD II). Within 2007 GOLD stages, each of the pairwise comparisons are
significantly different for exacerbations, hospitalisations (p,0.001) and all-cause mortality (pf0.002).
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FIGURE 1 Frequency distribution of the chronic obstructive pulmonary patients studied here according to the 2007 (a)
or 2011 (b) Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations. Two subjects were
classified as having GOLD stage I but were not included in a) or b). c) Shows the cumulative distribution of the four
patient groups for the 2011 GOLD classification within each 2007 GOLD stage.
COPD | A. AGUSTI ET AL.
DOI: 10.1183/09031936.00195212 639
Similarly, within 2011 GOLD groups (all patients), each of the pairwise comparisons are also significantly
different for exacerbations (p,0.001), but not for hospitalisations or mortality, which were different in A
and D (pf0.010), but similar in B and C patients, despite group B having better lung function and fewer
exacerbations; yet, group B also had, at baseline, the highest prevalence of comorbidities (table 1),
particularly cardiac comorbidities (online supplementary table 2E), and of patients with persistent systemic
inflammation (fig. 4), defined as we described previously [14].
Compared with the 2007 GOLD classification, the 2011 GOLD classification had a higher concordance
probability (95% CI) for predicting exacerbations (0.591 (0.577–0.605) versus 0.570 (0.558–0.583);
p50.003) and hospitalisations (0.659 (0.640–0.679) versus 0.628 (0.610–0.646); p50.001); both
classifications were similar for the prediction of all-cause mortality (0.596 (0.562–0.630) versus 0.614
(0.576–0.653); p50.32).
Because there is limited information in the ECLIPSE database on specific causes of death [1, 7], we used a
Cox proportional hazards regression model to identify factors associated with increased risk of mortality.
These included more severe airflow limitation, high age, low BMI, high FFMI, increased number of
comorbidities, and lower exercise capacity (table 2). Interestingly, GOLD B patients had less airflow
TABLE 1 Outcomes of the four groups of patients as per the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations [2].
Distribution 2011 GOLD groups p-value
A B C D
Patients 495 (24) 293 (14) 483 (23) 830 (40)
GOLD 2011 assessment variables
mMRC dyspnoea score 0.6¡0.5 2.3¡0.6 0.8¡0.4 2.6¡0.7 ,0.001
FEV1 % predicted 64.2¡8.1 61.6¡8.2 42.2¡11.5 37.2¡11.2 ,0.001
Exacerbations previous 12 months 0.2¡0.4 0.3¡0.5 1.0¡1.4 1.3¡1.4 ,0.001
Demographics
Age years 63.2¡7.2 64.1¡7.3 62.9¡7.2 63.6¡6.9 0.078
Female 191(39) 106(36) 149(31) 280(34) 0.07
Body mass index kg?m-2 26.7¡4.8 28.5¡6.1 25.2¡4.9 26.5¡6.1 ,0.001
Fat-free mass index kg?m-2 17.3¡2.5 18.0¡3.5 16.7¡2.5 17.1¡2.9 ,0.001
Smoking, pack-years 48.0¡29.4 47.5¡25.8 45.2¡23.2 51.1¡27.7 ,0.001
Current smoker 188 (38) 101 (34) 207 (43) 267 (32) 0.001
Symptoms
Chronic bronchitis 131 (26) 104 (35) 182 (38) 318 (38) ,0.001
SGRQ-C total score 31.9¡17.3 55.3¡15.5 44.6¡16.8 62.2¡15.6 ,0.001
CESD total score 8.3¡8.0 13.8¡9.4 9.5¡8.2 13.5¡9.7 ,0.001
Self-reported comorbidities
With any comorbidity 383 (77) 248 (85) 350 (72) 690 (83) ,0.001
Number of comorbidities 2.0¡1.7 2.8¡2.2 1.7¡1.7 2.3¡1.9 ,0.001
Physiology
FEV1 % reversibility 11.4¡13.2 11.8¡12.9 10.3¡13.5 10.2¡14.5 0.035
SaO2 % 95.7¡2.1 95.1¡2.5 94.4¡3.2 93.7¡3.2 ,0.001
6-min walking distance m 440¡106 360¡101 408¡106 307¡114 ,0.001
BODE index 0.8¡0.8 2.7¡1.2 2.6 (1.2 5.1¡1.6 ,0.001
Imaging
% LAA -950 HU 11.8¡9.7 12.5¡9.9 18.9¡11.5 22.5¡12.8 ,0.001
Outcomes during 3-year follow-up
ECOPD per year 0.6¡0.8 0.9¡1.0 1.3¡1.4 1.7¡1.7 ,0.001
o1 hospitalisation 56 (11) 71 (25) 143 (30) 378 (46) ,0.001
Mortality rate 22 (4) 28 (10) 41 (8) 114 (14) ,0.001
Mortality rate per 100 patient-years 1.6¡7.4 3.7¡11.5 3.2¡10.5 5.5¡13.7 ,0.001
Rate of annual FEV1 decline mL per year -33.4 (46.2) -38.0 (47.0) -30.2 (45.5) -31.9 (34.6) 0.157
Data are presented as n (%) or mean¡SD, unless otherwise stated. mMRC: dyspnoea score according to the modified Medical Research Council
questionnaire; FEV1; forced expiratory volume in 1 s; SGRQ-C: St George’s Respiratory Questionnaire for chronic obstructive pulmonary disease
(COPD) patients; CESD: Center for Epidemiological Studies Depression Scale; SaO2; arterial oxygen saturation; BODE: body mass index, airflow
obstruction, dyspnoea, exercise capacity index; % LAA: percentage of low attenuation areas (i.e. emphysema) in the computed tomography; ECOPD:
exacerbation of COPD.
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limitation and higher BMI than GOLD C patients, but were older, had a higher FFMI, more comorbidities,
and poorer exercise capacity (table 1). These differences may contribute to their similar mortality during
follow-up (fig. 3). A similar set of covariates (FEV1 % pred, age, BMI, number of comorbidities, prior
exacerbation history, arterial oxygen saturation and dyspnoea) were associated with increased risk of
hospitalisation (table 2). For each of these covariates, differences were also noted between GOLD B and
GOLD C patients (table 1).
Two final aspects of our analysis deserve comment. First, there were no significant differences between
gender across the four groups for mortality or hospitalisation during follow up (online supplementary
table 1E) but females had a higher exacerbation rate than males (pf0.017). Secondly, if only 2007 GOLD
stage II patients (FEV1 .50% of reference) are considered (fig. 1c), the 2011 GOLD proposal lacks
discriminant power to predict exacerbations in C2 and D2 patients, the risk of hospitalisation is similar and
intermediate in C2 and B patients and, interestingly, mortality during follow-up was zero in C2 patients
(fig. 3g–i).
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Discussion
The 2011 GOLD recommendations have proposed a novel, multidimensional strategy to assess disease
severity and guide therapy in COPD [2]. Because this proposal was mostly based on expert opinion [2],
several recent studies have used existing COPD cohorts to test it [3, 5, 6]. Our study confirms some of their
results and extends them by presenting novel aspects not previously explored.
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Previous findings
Our results reproduce and support five previous observations. 1) In keeping with LANGE et al. [5] we found
that the new 2011 GOLD classification assesses disease severity differently from the previous 2007 proposal,
since more individuals are categorised in the more severe group (fig. 1a and b). This is not surprising if the
multidimensional nature of the 2011 GOLD proposal is considered [2]. 2) The prevalence of the four 2011
GOLD groups in our study (fig. 1b) was similar to that reported in previous COPD cohorts recruited from
hospital clinics [3, 6], but clearly different from that described in COPD patients identified in the general
population, where group A clearly predominates [5]. 3) In agreement with previous reports [3, 5] we found
that a low FEV1 (,50% reference) was the main reason for classifying patients as high risk (C and D
groups). 4) We reproduced previous observations (fig 3d–f) indicating that the new 2011 GOLD assessment
proposal predicts future exacerbations appropriately [3, 5]. Likewise, in keeping with LANGE et al. [5], we
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TABLE 2 Cox proportional hazards regression analyses for all-cause mortality and hospitalisations during follow-up
Independent variable Estimate p-value
Mortality
Forced expiratory volume in 1 s % predicted 0.982 (0.969–0.996) 0.011
Age years 1.052 (1.021–1.085) ,0.001
Body mass index kg?m-2 0.931 (0.882–0.983) 0.01
Fat-free mass index kg?m-2 1.146 (1.036–1.267) 0.008
Number of comorbidities 1.100 (1.001–1.210) 0.048
6-min walking distance m 0.997 (0.996–0.999) 0.002
Hospitalisations
Modified Medical Research Council dyspnoea score 1.246 (1.119–1.387) ,0.001
Forced expiratory volume in 1 s % predicted 0.974 (0.966–0.982) ,0.001
Exacerbations in previous 12 months 1.195 (1.123–1.270) ,0.001
Age years 1.021 (1.005–1.038) 0.01
Body mass index kg?m-2 0.979 (0.960–0.999) 0.04
Hypertension 0.669 (0.526–0.851) 0.001
Angina 0.565 (0.371–0.858) 0.007
Osteoarthritis 0.695 (0.489–0.987) 0.042
Diabetes 0.604 (0.392–0.932) 0.023
Depression requiring treatment 0.657 (0.473–0.912) 0.012
Number of comorbidities 1.209 (1.113–1.314) ,0.001
Arterial oxygen saturation % 0.929 (0.902–0.956) ,0.001
Data are presented as hazard ratio (95% confidence interval), unless otherwise stated.
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observed that mortality was similar in groups B and C (fig. 4), despite the former having, by definition,
better lung function and fewer exacerbations [2]. We think that this is a clear example of how the new 2011
GOLD assessment proposal goes beyond FEV1 and identifies a group of patients who, despite the presence
of moderate airflow limitation, are at high risk of mortality. SORIANO et al. [6] reported a similar observation
over 3- but not at 10-year follow-up, raising the possibility of different causes of death at different time-
points during follow-up. The specific causes of death were not investigated by SORIANO et al. [6], but LANGE
et al. [5] reported that B patients often died of cardiovascular disease and cancer. In keeping with this
observation, we also found that B patients showed the highest prevalence of comorbidities and included
more patients with persistent systemic inflammation (fig. 4, table 1). The former is known to have a direct
and significant impact on survival in COPD [19] and the latter has been recently shown to increase
mortality six-fold, irrespective of the severity of the pulmonary abnormalities present [14]. These
observations may have clinical implications for the practitioner, since B patients appear to be a unique
group that deserve special attention in order to understand the origin of their greater symptoms, which are
likely to relate to the presence of comorbidities, which may occur in patients with moderate airflow
limitation [1], and need to be actively looked for and treated adequately if present [2]. 5) The observation
that despite having frequent exacerbations and requiring frequent hospitalisations, C2 patients have a
mortality of zero during follow-up (fig. 3) is also of clinical interest and in keeping with the observations by
LANGE et al. [5].
Novel observations
Our study extends previous reports [3, 5, 6] by providing potentially relevant information on six aspects not
investigated before.1) We found that the four 2011 GOLD groups differed in many clinical, functional,
imaging and biological characteristics in addition to those used for their categorisation (tables 1 and online
supplementary table 2E). Interestingly, some of them (comorbidities and systemic inflammation) are more
prevalent in the two high symptom groups (B and D), whereas others (emphysema and low arterial oxygen
saturation) are more prevalent in the two high risk groups (C and D) (tables 1 and online supplementary
table 2E). Although both HAN et al. [3] and LANGE et al. [5] identified some of these differences, the level of
characterisation of the participants in ECLIPSE is much more detailed so, this information constitutes an
important repository of data (tables 1 and online supplementary tables 2E, 3E and 4E) of potential use for a
better understanding of the disease and for the design of future studies. 2) Our analysis is the first to
investigate the temporal stability of the four 2011 GOLD groups. We observed that a relative majority of A
and D patients do actually remain in their original classification, whereas B and C patients present higher
temporal variability (fig. 2). These changes can be due to either disease progression, or the beneficial effect
of therapy but, in any case, this observation provides evidence of the degree of heterogeneity of the natural
history of the disease and may highlight a potential window of opportunity for therapeutic intervention. 3)
Also not explored previously [3, 5, 6], we found that the 2011 GOLD assessment proposal does not separate
the COPD cohort into groups that differ in their rate of FEV1 decline (table 1). This suggests that further
segmentation of the COPD population beyond that proposed by 2011 GOLD assessment may be required to
fully describe COPD heterogeneity, since several recent studies [20, 21], including an analysis of the
ECLIPSE cohort [15], have clearly shown that the rate of FEV1 decline varies among COPD patients. 4) No
previous study has investigated the relationship of the four 2011 GOLD groups with hospitalisations during
follow-up. We found that, similarly to mortality, hospitalisations were less prevalent in A, most in D and
intermediate and similar in the B and C groups (fig. 3). As in the case of mortality discussed above, this
observation emphasises a, sometimes overlooked, fact; i.e. that patients with COPD may require
hospitalisation (and/or die) for reasons not directly related to COPD (comorbidities). Because they are
amenable to therapy [22], this observation supports the emphasis made by the 2011 GOLD document on
the importance of actively looking for, and adequately treating if present, the comorbidities known to
frequently occur in COPD patients [2]. 5) Since ECLIPSE does not have information on specific causes of
death, we explored factors associated with increased risk of mortality (and hospitalisations) using a Cox
proportional hazards regression model. Interestingly the identified risk factors were similar for mortality
and hospitalisations (table 2). The fact that they were distributed relatively evenly between B and C patients
(tables 1 and online supplementary table 2E) may in part explain the relatively similar outcomes exhibited
by these two groups despite their different severities of airflow limitation and/or past history of
exacerbations, and may help clinicians to assess the risk of individual patients. 6) We explored, for the first
time, the potential gender differences among 2011 GOLD groups. We found that their frequency
distribution was not different in males or females (online supplementary table 1E). Furthermore, we
observed that there were no significant gender differences for mortality or hospitalisations although,
interestingly, females had a higher (pf0.017) exacerbation rate during follow-up than males (online
supplementary table 1E).
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Potential limitations
The following potential limitations of our study deserve comment. 1) Like all previous studies [3, 5, 6], our
analysis took advantage of an existing cohort assembled for different purposes, so it might not mirror the
population of COPD patients at large. 2) Because patients enrolled in the ECLIPSE study were mostly
recruited from hospital clinics and were treated according to the attending physician, our results may not be
directly generalised to untreated patients or patients with milder disease (i.e. GOLD stage I). However, it is
of interest that LANGE et al. [5] reported similar observations in patients recruited from the general
population with a skewed distribution towards milder disease (77% classified in the A group). 3) Because of
the inclusion criteria used in the ECLIPSE study (age 40–75 years, baseline post-bronchodilator FEV1
,80% of the predicted value, baseline post-bronchodilator FEV1/FVC f0.7 and a smoking history of o10
pack-years [7]), it is possible that a small fraction of A and B patients analysed here may be above the lower
limit of the normal. Yet, all of them were diagnosed of COPD by their attending physicians considering
their exposure to risk factors and current clinical symptomatology. 4) Comorbidities were self-reported and
we lack information on specific causes of death, so some of our observations and interpretations require
prospective validation in future studies.
Conclusions
The different longitudinal behaviour of group A versus B, and C versus D (both pairs with similar FEV1
values) supports the 2011 GOLD proposal of assessing COPD patients by more than just the degree of
airflow limitation. However the assumption that symptoms do not equate to risk appears to be naı¨ve, as
groups B and C carry equally poor clinical outcomes though for different reasons. The latter may explain
why group B patients are those most likely to switch group over time.
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